300149.SHE ChemPartner PharmaTech Co Ltd
- Market cap
- CNY 4.49B
- P/E
- -
- P/B
- 3.38x
- ROE
- -1.3%
- Dividend yield
- 0.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300149.SHE undervalued?
Graham numberThe Graham number of ChemPartner PharmaTech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ChemPartner PharmaTech Co Ltd fundamental analysis
No fundamental analysis for ChemPartner PharmaTech Co Ltd yet.
ChemPartner PharmaTech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ChemPartner PharmaTech Co Ltd
ChemPartner PharmaTech Co.,Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehensive chemical drug research and development and biological drug services for pha…
Full company profileChemPartner PharmaTech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ChemPartner PharmaTech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 259M | 275M | 997M | 1.33B | 1.48B | 1.69B | 1.33B | 1.14B | 970M | 1.13B | 1.26B |
| Gross Profit | 131M | 126M | 427M | 507M | 568M | 536M | 337M | 295M | 212M | 325M | 327M |
| Operating Income | 68.9M | 53.7M | 195M | 208M | 215M | 89.6M | -61.5M | -37.5M | -42.7M | 39.1M | 32.6M |
| EBITDA | - | 86.7M | 277M | 297M | 350M | -91.4M | 1.00B | -769M | -73.8M | 149M | 773K |
| Net Income | 65.0M | 57.8M | 161M | 139M | 155M | -402M | 379M | -917M | -226M | 13.4M | -17.8M |
| EPS | - | 0.14 | 0.32 | 0.28 | 0.31 | -0.80 | 0.76 | -1.83 | -0.45 | 0.03 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 793M | 1.04B | 3.35B | 3.77B | 4.12B | 4.22B | 3.82B | 2.43B | 2.00B | 2.03B | 2.15B |
| Total Liabilities | 23.2M | 208M | 1.14B | 1.46B | 1.67B | 2.23B | 1.44B | 973M | 758M | 733M | 791M |
| Shareholders' Equity | 770M | 812M | 2.19B | 2.29B | 2.43B | 1.96B | 2.36B | 1.44B | 1.21B | 1.28B | 1.33B |
| Cash & Short-term Investments | 112M | 291M | 191M | 201M | 259M | 160M | 762M | 347M | 368M | 412M | 423M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 71.3M | 63.4M | 243M | 215M | 343M | 378M | 262M | 151M | 168M | 190M | - |
| Capital Expenditure | 10.5M | 4.21M | 110M | 254M | 394M | 286M | 336M | 201M | 69.2M | 62.5M | 88.5M |
| Free Cash Flow | - | 59.2M | 133M | -39.2M | -50.9M | 92.2M | -73.7M | -50.3M | 99.0M | 128M | 46.3M |
| Ratios | |||||||||||
| ROE | 8.4% | 7.1% | 7.4% | 6.1% | 6.4% | -20.5% | 16.0% | -63.8% | -18.7% | 1.1% | -1.3% |
| ROA | 8.2% | 5.5% | 4.8% | 3.7% | 3.7% | -9.5% | 9.9% | -37.7% | -11.3% | 0.7% | -0.8% |
| Net Profit Margin | 25.1% | 21.0% | 16.2% | 10.5% | 10.4% | -23.8% | 28.5% | -80.5% | -23.3% | 1.2% | -1.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ChemPartner PharmaTech Co Ltd dividends
- Dividend yield
- 0.06%
- Forward dividend
- -
- Payout ratio
- 21.6%
- Ex-dividend date
- Jun 1, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.90M | 0.01 | 21.6% |
| 2024 | CNY 2.88M | 0.01 | - |
| 2023 | CNY 6.24M | 0.01 | - |
| 2022 | CNY 37.4M | 0.07 | 9.9% |
| 2021 | CNY 81.1M | 0.16 | - |
| 2020 | CNY 57.1M | 0.11 | 36.9% |
| 2019 | CNY 79.7M | 0.16 | 57.4% |
| 2018 | CNY 45.8M | 0.09 | 28.4% |
| 2017 | CNY 21.1M | 0.05 | 36.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 14:10 on May 21, 2015.
Who owns ChemPartner PharmaTech Co Ltd
- Insiders 29.39%
- Institutions 1.68%
- Public & others 68.93%
- Shares outstanding 505M
- Free float 310M
ChemPartner PharmaTech Co Ltd company profile
- Company name
- ChemPartner PharmaTech Co Ltd
- Ticker
- 300149.SHE
- ISIN
- CNE100000Y27
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 22, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,771
- Fiscal year end
- December
- Address
- Exchange Square, Guangzhou, China, 510031
- Phone
- 86 20 6681 1798
- Website
- cppt.com.cn
About ChemPartner PharmaTech Co Ltd
ChemPartner PharmaTech Co.,Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehensive chemical drug research and development and biological drug services for pharmaceutical companies, biotechnology companies, and scientific research institutions. The company was formerly known as Quantum Hi-Tech (China) Biological Co., Ltd. and changed its name to ChemPartner PharmaTech Co.,Ltd. in September 2020. ChemPartner PharmaTech Co.,Ltd. was founded in 2000 and is headquartered in Guangzhou, China.
ChemPartner PharmaTech Co Ltd management
3- Mr. Swee Lian WooGM, Board Secretary & Chairman · born 1961
- Mr. Yunqun ZhaCFO & Accounting Supervisor · born 1979
- Mr. Wang Long ChenVP & Director · born 1972